

## 1 **The transferability of lipid loci across African, Asian and European cohorts**

2 Nikita Telkar<sup>1,25</sup>, Theresa Reiker<sup>2,3,4,5,25</sup>, Robin G. Walters<sup>6,7</sup>, Kuang Lin<sup>7</sup>, Anders Eriksson<sup>8</sup>, Deepti  
3 Gurdasani<sup>2</sup>, Arthur Gilly<sup>2,9</sup>, Lorraine Southam<sup>2,9,10</sup>, Emmanouil Tsafantakis<sup>11</sup>, Maria Karaleftheri<sup>12</sup>, Janet  
4 Seeley<sup>13,14,15</sup>, Anatoli Kamali<sup>15</sup>, Gershim Asiki<sup>15,16,17</sup>, Iona Y. Millwood<sup>6,7</sup>, Michael Holmes<sup>6,7</sup>, Huaidong Du<sup>6,7</sup>,  
5 Yu Guo<sup>18</sup>, Understanding Society Scientific Group<sup>19</sup>, Meena Kumari<sup>19</sup>, George Dedoussis<sup>20</sup>, Liming  
6 Li<sup>21</sup>, Zhengming Chen<sup>7</sup>, Manjinder S. Sandhu<sup>22</sup>, Eleftheria Zeggini<sup>2,9</sup>, Karoline Kuchenbaecker<sup>2,23,24\*</sup>

7

8 <sup>1</sup> Department of Genetics, Evolution and Environment, University College London, London WC1E 6BT,  
9 UK

10 <sup>2</sup> Department of Human Genetics, Wellcome Sanger Institute, Hinxton, CB10 1SA, UK

11 <sup>3</sup> Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK

12 <sup>4</sup> Swiss Tropical and Public Health Institute, Basel, Switzerland

13 <sup>5</sup> University of Basel, Basel, Switzerland

14 <sup>6</sup> Medical Research Council Population Health Research Unit (MRC PHRU), Nuffield Department of  
15 Population Health, University of Oxford, Oxford, UK

16 <sup>7</sup> Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population  
17 Health, University of Oxford, Oxford, UK

18 <sup>8</sup> Department of Medical and Molecular Genetics, King's College London, London SE1 9RT, UK

19 <sup>9</sup> Institute of Translational Genomics, Helmholtz Zentrum München, German Research Center for  
20 Environmental Health, Neuherberg, Germany

21 <sup>10</sup> Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK

22 <sup>11</sup> Anogia Medical Centre, Anogia, 740 51, Greece

23 <sup>12</sup> Echinops Medical Centre, Echinops, Xanthi 67300, Greece

24 <sup>13</sup> Department of Global Health and Development, London School of Hygiene & Tropical Medicine,  
25 London WC1E 7HT, UK

26 <sup>14</sup> Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London WC1E  
27 7HT, UK

28 <sup>15</sup> Medical Research<sup>1</sup> Council/Uganda Virus Research Institute and London School of Hygiene  
29 (MRC/UVRI and LSHTM), Uganda Research Unit, Entebbe, Uganda

30 <sup>16</sup> African Population and Health Research Center, Nairobi, Kenya

31 <sup>17</sup> Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden

32 <sup>18</sup> Chinese Academy of Medical Sciences, Beijing 100730, China

33 <sup>19</sup> Institute for Social and Economic Research, University of Essex, Wivenhoe Park, Colchester, Essex,  
34 UK

35 <sup>20</sup> Department of Nutrition and Dietetics, School of Health Science and  
36 Education, Harokopio University of Athens, Greece

37 <sup>21</sup> Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing  
38 100191, China

39 <sup>22</sup> Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK

40 <sup>23</sup> Division of Psychiatry, University College of London, London W1T 7NF, UK

41 <sup>24</sup> UCL Genetics Institute, University College London, London WC1E 6BT, UK

42 <sup>25</sup> These authors contributed equally to this work

43 \* Correspondence to: [k.kuchenbaecker@ucl.ac.uk](mailto:k.kuchenbaecker@ucl.ac.uk)

44 **Abstract**

45 The majority of genetic studies for cardiometabolic traits were based on samples with European  
46 ancestry. Our aim was to assess whether genetic variants associated with blood lipids, a major risk  
47 factor for CVD, are shared across different populations.

48 We compared genetic associations with lipids between samples from Uganda (N=6,407), China  
49 (N=21,295), Japan (N=162,255), the UK (N=9,961) and Greece (N=3,586). Using simulations, we  
50 established trans-ethnic colocalization as a method to distinguish shared from population-specific  
51 trait loci.

52 Genetic correlations for HDL, LDL and triglycerides between European ancestry and Asian cohorts  
53 were close to 1. A polygenic score based on established LDL-cholesterol-associated loci from European  
54 discovery samples had consistent effects on serum levels in samples from the UK, Uganda and Greek  
55 population isolates ( $r=0.23$  to  $0.28$ ,  $p<1.9\times 10^{-14}$ ). Overall, ~75% of the major lipid loci from European  
56 discovery studies displayed evidence of replication at  $p<10^{-3}$ , except triglyceride loci in the Ugandan  
57 samples of which only 10% replicated. Specific replicating loci were identified using trans-ethnic  
58 colocalization. Ten of the fourteen lipid loci that did not replicate in the Ugandan population had  
59 pleiotropic associations with BMI in European ancestry samples while none of the replicating loci did.  
60 While lipid associations were highly consistent across European and Asian populations, there was a  
61 lack of replication particularly for established triglyceride loci in the Ugandan population. These loci  
62 might affect lipids by modifying food intake or metabolism in an environment offering diets rich in  
63 certain nutrients. This suggests that gene-environment interactions could play an important role for  
64 the transferability of complex trait loci.

## 65 **Introduction**

66 Cardiovascular disease (CVD) is one of the leading causes of death worldwide<sup>1</sup>. As the predictive ability  
67 of common variants for CVD and cardiometabolic traits improves, risk prediction in clinical settings  
68 finds increasing consideration<sup>2,3</sup>. The foundations for this were provided by genome “white”  
69 association studies: the majority of samples included in these studies were British or US-Americans  
70 with European ancestry<sup>4,5</sup> which does not accurately representation the ethnically and ancestrally  
71 diverse populations of these nations. Moreover, three quarters of CVD deaths occur in low- and  
72 middle-income countries with incidences further rising<sup>6</sup>. Consequently, it is important to determine  
73 whether cardiometabolic trait loci are transferable to other populations. We focussed on blood lipids,  
74 a major cardiovascular risk factor.

75 Previous research assessed the effects of different allele frequencies and linkage disequilibrium (LD)  
76 on genetic associations across ancestry groups<sup>7</sup>. Here we ask the fundamental question whether  
77 causal variants for lipid biomarkers are shared across populations. Heterogeneity in effects of variants  
78 could result from epistasis or gene-environment interactions. However, differences in LD structure  
79 between populations make it difficult to compare associations between ancestry groups because the  
80 observable effect of a variant depends on its correlation with the causal variant(s)<sup>7</sup>. Differences in  
81 frequency also impact on the power to detect associations in other ancestry groups.

82 We employed several strategies which account for these effects to quantify the extent to which  
83 genetic variants affecting lipid biomarkers are shared between individuals from Europe/North  
84 America, Asia, and Africa. We assessed the transferability of individual signals and compared  
85 association patterns across the genome using data from the African Partnership for Chronic Disease  
86 Research – Uganda (APCDR-Uganda, N=6,407)<sup>8</sup>, China Kadoorie Biobank (CKB, N=21,295)<sup>9</sup>, the  
87 Hellenic Isolated Cohorts (HELIC-MANOLIS, N=1,641 and HELIC-Pomak, N=1,945)<sup>10,11</sup>, and the UK  
88 Household Longitudinal Study (UKHLS, N=9,961)<sup>12</sup>. We also used summary statistics from Biobank  
89 Japan (BBJ, N=162,255)<sup>13</sup> and the Global Lipid Genetics Consortium (European ancestry, GLGC2013  
90 N=188,577, GLGC2017 N=237,050)<sup>14,15</sup>.

91

## 92 **Results**

93 We assessed replication rates across established lipid-associated variants in different populations. We  
94 distinguished major lipid loci, i.e. those with  $p < 10^{-100}$  in the largest European ancestry GWAS. In this  
95 context, replication was operationalised as at least one variant from the credible set associated at  
96  $p < 10^{-3}$  in the target study. As a benchmark, we also assessed replication in two European ancestry  
97 studies. We found evidence of replication for 76.5% of major HDL loci in these two studies (Table 1).  
98 For the non-European groups replication rates ranged from 70.6 to 82.4%. Similar replication rates  
99 were observed for LDL loci (61.5-76.9%). For major triglycerides (TG) loci, replication rates ranged  
100 from 78.9 to 94.7%, except in APCDR-Uganda. Only 10.5% of these loci showed evidence of replication  
101 in that sample. Replication rates for known loci with  $p \geq 10^{-100}$  in the discovery set were generally  
102 moderate to low. However, Biobank Japan, the largest study, had markedly higher replication rates  
103 for these loci than the other studies.

104

105 Trans-ethnic genetic correlations were estimated between the three largest studies, China Kadoorie  
106 Biobank, Biobank Japan and GLGC2013. Correlations were high for each biomarker and were not  
107 significantly different from 1 (Figure 1, Supplementary Table 1). We also compared associations across  
108 biomarkers. This consistently showed negative genetic correlations between TG associations and HDL  
109 associations, with estimates ranging from  $r_{\text{gen}} = -0.48$  to  $r_{\text{gen}} = -0.86$ .

110

111 In order to assess patterns of sharing of risk alleles for the smaller studies, we constructed polygenic  
112 scores based on the established lipid loci from discovery samples with European ancestry and  
113 estimated the score associations with levels of HDL, LDL and TG in HELIC, APCDR-Uganda and also  
114 UKHLS as a benchmark (Figure 2). All genetic scores were significantly associated with their respective  
115 target lipid in the three European samples with largely consistent correlation coefficients and mutually  
116 overlapping 95% confidence intervals (CIs) (Table 2). For HDL, LDL and TG, the estimated correlation

117 coefficients had a range of 0.27-0.28, 0.23-0.28 and 0.20-0.24, respectively. In APCDR-Uganda, the  
118 strongest association was observed for LDL ( $r=0.28$ ,  $SE=0.01$ ,  $p=1.9 \times 10^{-107}$ ). The HDL association was  
119 attenuated compared to the European samples ( $r=0.12$ ,  $SE=0.01$ ,  $p=6.1 \times 10^{-22}$ ). The effect of the TG  
120 score was markedly weaker ( $r=0.06$ ,  $SE=0.01$ ,  $p=4.5 \times 10^{-7}$ ). We also assessed associations between a  
121 given score and levels of each of the other biomarkers (Supplementary Table 2). In line with the trans-  
122 ethnic genetic correlation results, we observed inverse associations between the HDL score and TG  
123 levels and vice versa in all studies, except APCDR-Uganda.

124

125 Differences in LD structure, MAF and sample size make it difficult to assess replication for individual  
126 loci. Therefore, we propose a new strategy to assess evidence for shared causal variants between two  
127 populations: trans-ethnic colocalization. For this we re-purposed a method that was originally  
128 developed for colocalization of GWAS and eQTL results: Joint Likelihood Mapping (JLIM)<sup>16</sup>. In order to  
129 assess its performance for GWAS results from samples with different ancestry, we carried out a  
130 simulation study. UK Biobank (UKB) was used as a European ancestry reference and compared to CKB  
131 and APCDR-Uganda. Phenotypes were simulated. In the simulations of distinct causal variants in the  
132 non-European and the reference group, the frequencies of false negatives were close to 0.05 as  
133 expected (Table 3), with an almost uniform distribution of p-values (Supplementary Figure 1). The  
134 power to detect shared associations was good for both populations: 73.1% for APCDR-Uganda and  
135 93.1% for CKB. To investigate whether the lower power for APCDR-Uganda could be due to its smaller  
136 sample size, we reran the analyses for CKB using a random subset of samples matching the sample  
137 size of APCDR-Uganda. The results were similar to the ones for the full CKB set, suggesting that the  
138 power of this trans-ethnic colocalization method decreases somewhat with greater genetic distance  
139 between the populations that are compared.

140

141 We applied trans-ethnic colocalization for established lipid loci to each study with UKHLS as the  
142 reference. There was evidence for significant ( $p_{\text{jlim}} < 0.05$ ) colocalization with at least one of the target

143 studies for about half of the major lipid loci (Supplementary Table 3). For several major TG loci, such  
144 as *GCKR* at 2p23.3 or *LPL* at 8p21.3, strong evidence of replication in the Asian studies was observed  
145 while there was no evidence of association in APCDR-Uganda (Figure 3b,c).

146 We compared major lipid loci showing evidence of replication in APCDR-Uganda with those not  
147 displaying any suggestion of replication. The proximal genes of replicating loci were enriched for lipid  
148 pathways including lipoprotein metabolism, lipid digestion mobilisation and transport, chylomicron-  
149 mediated lipid transport and metabolism of lipids and lipoproteins. The proximal genes of the non-  
150 replicating loci were enriched for several other pathways in addition to lipid metabolism, including  
151 SHP2 signalling, ABV3 integrin pathway, cytokine signalling in immune system, cytokine-cytokine  
152 receptor interaction and transmembrane transport of small molecules (Supplementary Figures 2 and  
153 3). We also assessed the associations of these loci with BMI in samples with European ancestry using  
154 publicly available summary statistics from the GIANT consortium<sup>17</sup> (N≥484,680) (Table 4). Ten of the  
155 fourteen non-replicating lipid loci had pleiotropic associations with BMI at a Bonferroni-adjusted  
156 threshold of  $p < 0.0024$ . None of the seven replicating lipid loci were associated with BMI. We also  
157 assessed four additional loci that were not significant in the trans-ethnic colocalization but displayed  
158 small regional p-values in APCDR-Uganda. Out of these only APOE was significantly associated with  
159 BMI ( $p = 4 \times 10^{-21}$ ).

160

161

## 162 Discussion

163 Recent efforts to increase global diversity in genetics studies have been vital, enabling this  
164 comprehensive cross-population comparison of genetic associations with blood lipids. We provide  
165 evidence for extensive sharing of genetic variants that affect levels of HDL- and LDL-cholesterol and  
166 triglycerides between individuals with European ancestry and samples from China, Japan and Greek  
167 population isolates. There was evidence of replication for about three quarters of major HDL and LDL  
168 loci (and triglyceride loci except in APCDR-Uganda). This was highly consistent across all studies.

169 Estimates of trans-ethnic genetic correlations between European, Chinese and Japanese samples were  
170 close to 1. Associations of polygenic scores for LDL were not attenuated in the Ugandan population  
171 compared to the UK samples. All PRS associations in the two Greek isolated populations were also  
172 highly consistent with those in the UK samples.

173 Previous studies that compared the direction of effect of established loci or assessed associations of  
174 polygenic scores reported differing degrees of consistency<sup>18-29</sup>. However, most of them were  
175 conducted in American samples with diverse ancestry, had smaller sample sizes and applied a single-  
176 variant look-up or PRS for a limited number of genetic variants. The high degree of consistency for  
177 cholesterol biomarkers we observed also contrasts with previously reported trans-ethnic genetic  
178 correlations for other traits, such as major depression, rheumatoid arthritis, or type 2 diabetes, which  
179 were substantially different from 1<sup>30,31</sup>. In a recent application using data from individuals with  
180 European and Asian ancestry from the UK and USA, the average genetic correlation across multiple  
181 traits was 0.55 (SE = 0.14) for GERA and 0.54 (SE=0.18) for UK Biobank<sup>32</sup>.

182 Differences in LD structure, MAF and sample size make it difficult to assess replication of individual  
183 loci. We therefore propose a new approach: trans-ethnic colocalization. Simulations showed  
184 consistent control of type I error rates as well as good power to detect associations. Colocalization  
185 identified shared causal variants even at loci where none of the individual variants were associated at  
186 stringent p-value thresholds. However, for many of the major lipid loci, more than one independent  
187 association signal was identified in discovery GWAS<sup>15</sup>. When these are located in close proximity to  
188 each other, they can interfere with the trans-ethnic colocalization analysis because JLIM assumes a  
189 single causal variant (Figure 3d). Therefore, future work should extend this approach to accommodate  
190 loci harbouring multiple causal variants. Using trans-ethnic colocalization, we showed that many  
191 established loci for triglycerides did not affect levels of this biomarker in Ugandan samples. This  
192 included loci associated at genome-wide significance in all the other studies, such as *GCKR* at 2p23.3  
193 or *LPL* at 8p21.3. The polygenic score for triglycerides had a weak effect on measured levels in APCDR-  
194 Uganda. This is unlikely to be an artefact of unreliable measurement: triglyceride levels had a heritable



195 component in this sample (SNP heritability of 0.25, SE=0.05<sup>8</sup>) and there were some genome-wide  
196 significant associations (Supplementary Figure 6e). It is also unlikely that this can be explained purely  
197 by differences in LD and MAF because they would affect the analyses of the other two biomarkers as  
198 well. Instead these discrepancies could be caused by gene-environment interactions. Most of the lipid  
199 loci that did not replicate in the Ugandans had pleiotropic associations with BMI in European ancestry  
200 samples while none of the replicating loci were linked to BMI. It is possible that the non-replicating  
201 variants affect the amount of food intake with downstream consequences for lipid levels. This might  
202 require an environment offering diets that are rich in certain nutrients. While the replicating genes  
203 were almost exclusively linked to pathways of lipid metabolism, the non-replicating genes were  
204 involved in a diverse pathways which is in line with hypothesis. An alternative explanation could be  
205 that the non-replicating loci are involved in metabolising nutrients given a particular diet that is not  
206 common in Uganda with downstream consequences for weight.

207 Overall, this could suggest an important role of environmental factors in modifying which genetic  
208 variants affect lipid levels. Studying the causes for discordant loci between groups has promise to  
209 further elucidate the biological mechanisms of lipid regulation and other complex traits. Applying  
210 genetic risk prediction within clinical settings is receiving increasing attention. Our findings  
211 demonstrate that the transferability of genetic associations across different ancestry groups and  
212 environmental settings should be assessed comprehensively for medically relevant traits. This is  
213 important in order to maximise the potential of precision medicine to yield health benefits that are  
214 widely shared within and across populations. Ongoing programs in underrepresented countries<sup>33</sup>,  
215 such as the Human Hereditary and Health in Africa Initiative<sup>34</sup>, and programs focussing on  
216 underrepresented groups, such as PAGE<sup>35</sup>, All of Us<sup>36</sup>, or East London Genes and Health<sup>37</sup>, could  
217 provide the basis for this.

218

219

220 **Methods**

221 *Data resources*

222 We included data from the Global Lipid Genetics Consortium (European ancestry samples only, GLGC),  
223 The UK Household Longitudinal Study (UKHLS), two isolated populations from the Greece Hellenic  
224 Isolated Cohorts (HELIC) , a rural West Ugandan population from the African Partnership for Chronic  
225 Disease Research (APCDR-Uganda) study, China Kadoorie Biobank (CBK), and Biobank Japan (BBJ). In  
226 addition, we used data from European ancestry samples from the eMERGE network to confirm  
227 replication rates of known loci. Raw genotype and phenotype data were available for UKHLS, APCDR-  
228 Uganda, CKB, HELIC-MANOLIS, HELIC-Pomak and eMERGE. Our analyses were based on summary  
229 statistics for BBJ and GLGC. Study details are provided in Supplementary Table 3.

230 Each study underwent standard quality control. Details of the genome-wide association analyses with  
231 lipid traits have been previously described for GLGC<sup>14</sup>, BBJ<sup>13</sup>, HELIC<sup>10</sup>, and UKHLS<sup>12</sup>. The association  
232 analysis for APCDR-Uganda was carried out within a mixed model framework using GEMMA<sup>38</sup>. Rank-  
233 based inverse normal transformation was applied to the lipid biomarkers after adjusting for age and  
234 gender. In China Kadoorie Biobank, lipid levels were regressed against eight principle components,  
235 region, age, age<sup>2</sup>, sex, and - for LDL and TG - fasting time<sup>2</sup>. LDL levels were derived using the Friedewald  
236 formula. After rank-based inverse normal transformation, the residuals were used as the outcomes in  
237 the genetic association analyses using linear regression. In eMERGE, biomarkers were adjusted for  
238 age, gender, kidney disease, statin use, type 2 diabetes status and disorders relating to growth  
239 hormones. Associations were carried out within a mixed model framework using BOLT-LMM<sup>39</sup>.  
240 Manhattan plots for eMerge, UKHLS, BBJ, CKB, and APCDR-Uganda are shown in Supplementary  
241 Figures 4-6.

242

243 *Established lipid loci*

244 A list of established lipid-associated loci was extracted from the latest Global Lipid Genetics  
245 Consortium (GLGC2017) publication<sup>15</sup> reporting 444 independent variants in 250 loci

246 associated at genome-wide significance with HDL, LDL, and triglyceride levels. We excluded three LDL  
247 variants where the association was not primarily driven by the samples with European ancestry. We  
248 assessed evidence of replication of the loci, applied trans-ethnic colocalization and used them to  
249 construct polygenic scores.

250

#### 251 *Replication of established lipid loci*

252 We assessed evidence of replication across these established lipid variants. For loci harbouring  
253 multiple signals, we only kept the most strongly associated variant. This left 170 HDL, 135 LDL and 136  
254 TG variants. We distinguished major loci, i.e. those with  $p < 10^{-100}$  in GLGC2017. For each lead SNP we  
255 identified all variants in LD ( $r^2 > 0.6$ ) based on the European ancestry 1000 Genomes data. We assessed  
256 whether the lead or any of the correlated variants, henceforth called credible set, displayed evidence  
257 of association in the target study. We used a p-value threshold of  $p < 10^{-3}$ . If this was not the case, we  
258 tested whether there was any other variant with evidence of association within a 50Kb window. While  
259 this p-value threshold might not be appropriate to provide conclusive evidence of replication for  
260 individual loci, we used this to test evidence of replication across sets of loci. As a benchmark, we  
261 computed the minimum p-value in 1000 random windows of 50Kb for each study. Less than 5% of  
262 random windows had a minimum  $p < 10^{-3}$  for the non-European ancestry studies.

263

#### 264 *Trans-ethnic genetic correlations*

265 We used the popcorn software<sup>30</sup> to estimate trans-ethnic genetic correlations between studies while  
266 accounting for differences in LD structure. This provides an indication of the correlation of causal-  
267 variant effect sizes across the genome at SNPs common in both populations. Variant LD scores were  
268 estimated for ancestry-matched 1000 Genomes data for each study combination. The estimation of  
269 LD scores failed for chromosome 6 for some groups. We therefore left out chromosome 6 from all  
270 comparisons. Variants with imputation accuracy  $r^2 < 0.8$  or  $MAF < 0.01$  were excluded. Popcorn did not

271 converge for any of the studies with less than 20,000 samples. Therefore, results are presented for  
272 comparisons between GLGC2013, CKB and BBJ. We estimated effect rather than impact correlations.

273

#### 274 *Polygenic scores*

275 We created polygenic scores based on the established lipid loci and assessed their associations with  
276 lipid levels in UKHLS, the HELIC cohorts, and APCDR-Uganda, as it was not possible to compute trans-  
277 ethnic genetic correlations for these studies. For HELIC and UKHLS, extreme values ( $\mu \pm 3 SD$ , sex  
278 stratified) were filtered. Age, age<sup>2</sup> and sex were adjusted for by regressing them on the biomarker  
279 values and using the residuals as outcomes for subsequent analyses. For each biomarker in each  
280 sample set, we checked normality and homoscedasticity. HDL and LDL were approximately normally  
281 distributed. For TG levels, a Box Cox transformation was used to normalize the data. APCDR-Uganda  
282 phenotype data were rank-based inverse normally transformed.

283 To make sure PRS were comparable across studies, we excluded variants that were absent, rare  
284 (MAF<0.01) or badly imputed ( $r^2<0.8$ ) in any of the studies and variants that had different alleles from  
285 those in the GLGC. The variant with larger discovery p-value from each correlated pair of SNPs ( $r^2>0.1$ )  
286 was also removed. This left 120, 103 and 101 variants for HDL, LDL and TG, respectively. We created  
287 trait-specific weighted PRS. The  $\beta$ -regression coefficients from SNP-trait associations in GLGC2017<sup>15</sup>  
288 were used as weights. All biomarkers and scores were scaled to mean=0 and standard deviation=1 for  
289 each study so that the regression coefficient represent estimates of the correlation between scores  
290 and biomarkers.

291 We carried out association analyses between each polygenic score and each biomarkers using a linear  
292 mixed model with random polygenic effect implemented in GEMMA<sup>38</sup> in order to account for  
293 relatedness and population structure. We used a Bonferroni correction to adjust for multiple testing  
294 of three PRS with three different biomarker outcomes ( $p<0.05/9=0.0056$ ).

295

#### 296 *Trans-ethnic colocalization*

318 Differences in allele frequency, LD structure and sample size make it difficult to assess whether a given  
319 GWAS hit replicates in samples with different ancestries. Therefore, we applied trans-ethnic  
320 colocalization. Colocalization methods test whether the associations in two studies can be explained  
321 by the same underlying signal even if the specific causal variant is unknown. The joint likelihood  
322 mapping (JLIM) statistic was developed by Chun and colleagues to estimate the posterior probabilities  
323 for colocalization between GWAS and eQTL signals and compare them to probabilities of distinct  
324 causal variants<sup>16</sup>:

$$325 \quad \Lambda = \sum_{i \in N_{\theta}^1(m^*)} L_1(i) \times \log \frac{L_1(i)L_2(i)}{\max_{j \in N_{\theta}^2(i)} L_1(i)L_2(j)}$$

*i* SNP

*m*\* lead SNP

$L_1(i)$  likelihood of SNP *i* being causal for trait 1

$L_2(i)$  likelihood of SNP *i* being causal for trait 2

$N_{\theta}^1(i), N_{\theta}^2(i)$  sets of SNPs in LD with *i*

$\theta$  LD threshold

326  
327 JLIM explicitly accounts for LD structure. Therefore, we assessed whether it is suitable for trans-ethnic  
328 colocalization. For samples with summary statistics, LD scores were estimated using ancestry matched  
329 samples from the 1000 Genomes Project v3. JLIM assumes only one causal variant within a region in  
330 each study. We therefore used a small windows of 50Kb for each known locus to minimise the risk of  
331 interference from additional association signals. Distinct causal variants were defined by separation  
332 in LD space by  $r^2 \geq 0.8$  from each other. We excluded loci within the major histocompatibility region  
333 due to its complex LD structure. We used a significance threshold of  $p < 0.05$  given the evidence of  
334 association of the established lipid loci in Europeans and the overall evidence for shared causal genetic  
335 architecture across populations for most lipid traits from our other analyses. We compared each  
336 target study to UKHLS because of their high level of homogeneity in terms of ancestry, biomarker  
337 quantification and study design.

338

339 *Simulation*

340 To test the power of trans-ethnic colocalization to detect associations shared between pairs of  
341 populations with different ancestry, we ran JLIM on two sets of simulated traits with realistic effect  
342 size and environmental noise level. The first set of simulations used the same causal variant in both  
343 populations, whereas the second set of simulations discordant causal variants, chosen randomly. We  
344 sampled 10,000 randomly chosen biallelic variants with MAF>0.05 and simulated random phenotypes  
345 in CKB, APCDR-Uganda und 50,000 individuals with British ancestry from UK Biobank. For each data  
346 set relatives were excluded. We also sub-sampled CKB to match the smaller number of individuals in  
347 APCDR-Uganda in order to test whether different performance is due to ancestry or sample size. We  
348 used a simple linear model to generate the phenotype for each individual i:

$$349 \quad y_i = \beta * (x_i - 1) + \eta_i$$

350 where y is the phenotype value,  $\beta$  is the effect size, x is the number of the alternate alleles carried at  
351 the locus and  $\eta_i \sim N(0, \sigma^2)$ , where  $\sigma^2$  is the variance of the environmental noise and  $Cov(\eta_i, \eta_j) = 0$ .  
352 We used  $\beta = 0.25$  and  $\sigma^2 = 1$ .

353

#### 354 *Comparison of replicating with non-replicating loci*

355 We aimed to assess whether there are systematic differences between loci that are shared between  
356 European ancestry samples and APCDR-Uganda and loci that are not. We identified all loci with  
357 evidence of replication based on the above definition that also had significant ( $p < 0.05$ ) colocalization.  
358 We only kept one variant per region. We contrasted them with loci where none of the evidence  
359 suggested replication:  $p > 0.05$  for colocalization, no variant with a lipid association at  $p < 10^{-3}$  in the  
360 region and the lead variant from the discovery study was not rare in APCDR-Uganda. We identified  
361 the nearest protein coding gene for each locus and carried out a pathway analyses for the two sets  
362 using FUMA<sup>40</sup>. We also assessed the associations of the lead variants with body mass index (BMI) in  
363 European ancestry samples using results from a meta-analysis between the GIANT consortium and UK  
364 Biobank<sup>17</sup>. We used a Bonferroni adjusted p-value threshold.

365

### 366 *Data availability*

367 The UKHLS EGA accession number is EGAD00010000918. Genotype-phenotype data access for UKHLS  
368 is available by application to Metadac ([www.metadac.ac.uk](http://www.metadac.ac.uk)). eMERGE is available through dbgap  
369 (study ID: phs000888.v1.p1). Summary statistics for GLGC  
370 (<http://csg.sph.umich.edu/abecasis/public/>) and Biobank Japan (<http://jenger.riken.jp/en/>) are  
371 publicly available. The HELIC genotype and WGS datasets have been deposited to the European  
372 Genome-phenome Archive (<https://www.ebi.ac.uk/ega/home>): EGAD00010000518;  
373 EGAD00010000522; EGAD00010000610; EGAD00001001636, EGAD00001001637. The APCDR  
374 committees are responsible for curation, storage, and sharing of the APCDR-Uganda data under  
375 managed access. The array and sequence data have been deposited at the European Genome-  
376 phenome Archive (EGA, <http://www.ebi.ac.uk/ega/>, study accession number EGAS00001000545,  
377 datasets EGAS00001001558 and EGAD00001001639 respectively) and can be requested through  
378 [datasharing@sanger.ac.uk](mailto:datasharing@sanger.ac.uk). Requests for access to phenotype data may be directed to  
379 [data@apcdr.org](mailto:data@apcdr.org).

380

### 381 **Supplemental data**

382 The supplemental data contain three figures and two tables.

383

### 384 **Funding and acknowledgements**

385 We would like to thank the participants and volunteers of the each of the studies. We appreciate the  
386 advice received from Brielin Brown regarding the use of Popcorn and from Shamil Sunyaev and Sung  
387 Chun regarding the suitability of JLIM for trans-ethnic colocalization.

388 This work was funded by the Wellcome Trust (WT098051), (212360/Z/18/Z), and the European  
389 Research Council (ERC-2011-StG 280559-SEPI). The MANOLIS study is dedicated to the memory of  
390 Manolis Giannakakis, 1978-2010. We thank the residents of the Pomak villages and of the  
391 Mylopotamos villages for taking part. The HELIC study has been supported by many individuals who

392 have contributed to sample collection (including Antonis Athanasiadis, Olina Balafouti, Christina  
393 Batzaki, Georgios Daskalakis, Eleni Emmanouil, Pounar Feritoglou, Chrisoula Giannakaki, Margarita  
394 Giannakopoulou, Kiki Kaldaridou, Anastasia Kaparou, Vasiliki Kariakli, Stella Koinaki, Dimitra Kokori,  
395 Maria Konidari, Hara Koundouraki, Dimitris Koutoukidis, Vasiliki Mamakou, Eirini Mamalaki, Eirini  
396 Mpamiaki, Nilden Selim, Nesse Souloglou, Maria Tsoukana, Dimitra Tzakou, Katerina Vosdogianni,  
397 Niovi Xenaki, Eleni Zengini), data entry (Thanos Antonos, Dimitra Papagrigoriou, Betty Spiliopoulou),  
398 sample logistics (Sarah Edkins, Emma Gray), genotyping (Suzannah Bumpstead, Robert Andrews,  
399 Hannah Blackburn, Doug Simpkin, Siobhan Whitehead), research administration (Anja Kolb-  
400 Kokocinski, Carol Smee, Danielle Walker) and informatics (Kathleen Stirrups, Martin Pollard, Josh  
401 Randall).

402 APCDR-Uganda was funded by the Wellcome Trust, The Wellcome Trust Sanger Institute (WT098051),  
403 the UK Medical Research Council (G0901213-92157, G0801566, and MR/K013491/1), and the Medical  
404 Research Council/Uganda Virus Research Institute Uganda Research Unit on AIDS core funding. We  
405 thank the African Partnership for Chronic Disease Research (APCDR) for providing a network to  
406 support this study as well as a repository for deposition of curated data. We also thank all study  
407 participants who contributed to this study.

408 The UK Household Longitudinal Study was funded by grants from the Economic & Social Research  
409 Council (ES/H029745/1) and the Wellcome Trust (WT098051). UKHLS is led by the Institute for Social  
410 and Economic Research at the University of Essex and funded by the Economic and Social Research  
411 Council. The survey was conducted by NatCen and the genome-wide scan data were analysed and  
412 deposited by the Wellcome Trust Sanger Institute.

413

414 The Understanding Society Scientific Group are Michaela Benzeval(1), Jonathan Burton(1), Nicholas  
415 Buck(1), Annette Jäckle(1), Meena Kumari(1), Heather Laurie(1), Peter Lynn(1), Stephen Pudney(1),  
416 Birgitta Rabe(1), Dieter Wolke(2)

417 1) Institute for Social and Economic Research



418 2) University of Warwick

419

## 420 **Declaration of interests**

421 The authors declare no competing interests.

422

## 423 **Web resources**

424 We have made code to run trans-ethnic colocalization using JLIM and simulations available through  
425 github: <https://github.com/KarolineKuchenbaecker/TEColoc>

426

## 427 **References**

- 428 1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex  
429 specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic  
430 analysis for the Global Burden of Disease Study 2013. *Lancet Lond. Engl.* **385**, 117–171 (2015).
- 431 2. Khera, A. V. *et al.* Genome-wide polygenic scores for common diseases identify individuals with  
432 risk equivalent to monogenic mutations. *Nat. Genet.* **50**, 1219–1224 (2018).
- 433 3. Kuchenbaecker, K. B. *et al.* Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer  
434 Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *J. Natl. Cancer Inst.* **109**, (2017).
- 435 4. MacArthur, J. *et al.* The new NHGRI-EBI Catalog of published genome-wide association studies  
436 (GWAS Catalog). *Nucleic Acids Res.* **45**, D896–D901 (2017).
- 437 5. Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nat. News* **538**, 161 (2016).
- 438 6. Bovet, P. & Paccaud, F. Cardiovascular Disease and the Changing Face of Global Public Health: A  
439 Focus on Low and Middle Income Countries. *Public Health Rev.* **33**, 397–415 (2011).
- 440 7. Martin, A. R. *et al.* Human Demographic History Impacts Genetic Risk Prediction across Diverse  
441 Populations. *Am. J. Hum. Genet.* **100**, 635–649 (2017).
- 442 8. Heckerman, D. *et al.* Linear mixed model for heritability estimation that explicitly addresses  
443 environmental variation. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 7377–7382 (2016).

- 444 9. Chen, Z. *et al.* China Kadoorie Biobank of 0.5 million people: survey methods, baseline  
445 characteristics and long-term follow-up. *Int. J. Epidemiol.* **40**, 1652–1666 (2011).
- 446 10. Gilly, A. *et al.* Cohort-wide deep whole genome sequencing and the allelic architecture of  
447 complex traits. *Nat. Commun.* **9**, 4674 (2018).
- 448 11. Gilly, A. *et al.* Very low depth whole genome sequencing in complex trait association studies.  
449 *Bioinforma. Oxf. Engl.* (2018). doi:10.1093/bioinformatics/bty1032
- 450 12. Prins, B. P. *et al.* Genome-wide analysis of health-related biomarkers in the UK Household  
451 Longitudinal Study reveals novel associations. *Sci. Rep.* **7**, 11008 (2017).
- 452 13. Kanai, M. *et al.* Genetic analysis of quantitative traits in the Japanese population links cell types  
453 to complex human diseases. *Nat. Genet.* **50**, 390–400 (2018).
- 454 14. Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels.  
455 *Nat. Genet.* **45**, 1274–1283 (2013).
- 456 15. Liu, D. J. *et al.* Exome-wide association study of plasma lipids in >300,000 individuals. *Nat.*  
457 *Genet.* **49**, 1758 (2017).
- 458 16. Chun, S. *et al.* Limited statistical evidence for shared genetic effects of eQTLs and autoimmune-  
459 disease-associated loci in three major immune-cell types. *Nat. Genet.* **49**, 600–605 (2017).
- 460 17. Pulit, S. L. *et al.* Meta-analysis of genome-wide association studies for body fat distribution in  
461 694,649 individuals of European ancestry. *Hum. Mol. Genet.* (2018). doi:10.1093/hmg/ddy327
- 462 18. Musunuru, K. *et al.* Multi-Ethnic Analysis of Lipid-Associated Loci: The NHLBI CARE Project. *PLoS*  
463 *ONE* **7**, (2012).
- 464 19. Teslovich, T. M. *et al.* Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids.  
465 *Nature* **466**, 707–713 (2010).
- 466 20. Dumitrescu, L. *et al.* Genetic Determinants of Lipid Traits in Diverse Populations from the  
467 Population Architecture using Genomics and Epidemiology (PAGE) Study. *PLoS Genet.* **7**, (2011).
- 468 21. Bryant, E. K. *et al.* A Multiethnic Replication Study of Plasma Lipoprotein Levels-Associated SNPs  
469 Identified in Recent GWAS. *PLoS ONE* **8**, (2013).

- 470 22. Wu, Y. *et al.* Trans-Ethnic Fine-Mapping of Lipid Loci Identifies Population-Specific Signals and  
471 Allelic Heterogeneity That Increases the Trait Variance Explained. *PLoS Genet.* **9**, (2013).
- 472 23. Wang, Z. *et al.* Genetic associations with lipoprotein subfraction measures differ by ethnicity in  
473 the multi-ethnic study of atherosclerosis (MESA). *Hum. Genet.* **136**, 715–726 (2017).
- 474 24. Keebler, M. E. *et al.* Association of Blood Lipids with Common DNA Sequence Variants at  
475 Nineteen Genetic Loci in the Multiethnic United States National Health and Nutrition  
476 Examination Survey III. *Circ. Cardiovasc. Genet.* **2**, 238–243 (2009).
- 477 25. Lanktree, M. B., Anand, S. S., Yusuf, S. & Hegele, R. A. Replication of genetic associations with  
478 plasma lipoprotein traits in a multiethnic sample. *J. Lipid Res.* **50**, 1487–1496 (2009).
- 479 26. Chang, M. *et al.* Racial/ethnic variation in the association of lipid-related genetic variants with  
480 blood lipids in the US adult population. *Circ. Cardiovasc. Genet.* **4**, 523–533 (2011).
- 481 27. Below, J. E. *et al.* Meta-analysis of lipid-traits in Hispanics identifies novel loci, population-  
482 specific effects, and tissue-specific enrichment of eQTLs. *Sci. Rep.* **6**, (2016).
- 483 28. Johnson, L., Zhu, J., Scott, E. R. & Wineinger, N. E. An Examination of the Relationship between  
484 Lipid Levels and Associated Genetic Markers across Racial/Ethnic Populations in the Multi-Ethnic  
485 Study of Atherosclerosis. *PLoS One* **10**, e0126361 (2015).
- 486 29. Marigorta, U. M. & Navarro, A. High Trans-ethnic Replicability of GWAS Results Implies Common  
487 Causal Variants. *PLoS Genet.* **9**, e1003566 (2013).
- 488 30. Brown, B. C., Ye, C. J., Price, A. L. & Zaitlen, N. Transethnic Genetic-Correlation Estimates from  
489 Summary Statistics. *Am. J. Hum. Genet.* **99**, 76–88 (2016).
- 490 31. Wray, N. R. *et al.* Genome-wide association analyses identify 44 risk variants and refine the  
491 genetic architecture of major depression. *Nat. Genet.* **50**, 668–681 (2018).
- 492 32. Galinsky, K. J. *et al.* Estimating cross-population genetic correlations of causal effect sizes. *Genet.*  
493 *Epidemiol.* (2018). doi:10.1002/gepi.22173
- 494 33. Hindorff, L. A. *et al.* Prioritizing diversity in human genomics research. *Nat. Rev. Genet.* **19**, 175–  
495 185 (2018).

- 496 34. Mulder, N. *et al.* H3Africa: current perspectives. *Pharmacogenomics Pers. Med.* **Volume 11**, 59–  
497 66 (2018).
- 498 35. Carlson, C. S. *et al.* Generalization and Dilution of Association Results from European GWAS in  
499 Populations of Non-European Ancestry: The PAGE Study. *PLoS Biol.* **11**, e1001661 (2013).
- 500 36. Program Overview - All of Us | National Institutes of Health. Available at:  
501 <https://allofus.nih.gov/about/about-all-us-research-program>. (Accessed: 28th December 2018)
- 502 37. Finer, S. *et al.* Cohort Profile: East London Genes & Health (ELGH), a community based  
503 population genomics and health study in people of British-Bangladeshi and -Pakistani heritage.  
504 *bioRxiv* (2018). doi:10.1101/426163
- 505 38. Zhou, X. & Stephens, M. Genome-wide efficient mixed-model analysis for association studies.  
506 *Nat. Genet.* **44**, 821–824 (2012).
- 507 39. Loh, P.-R., Kichaev, G., Gazal, S., Schoech, A. P. & Price, A. L. Mixed-model association for  
508 biobank-scale datasets. *Nat. Genet.* **50**, 906–908 (2018).
- 509 40. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and  
510 annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).
- 511

512 **Figures**

513 **Figure 1. Trans-ethnic genetic correlations** for associations with high-density lipoprotein (HDL), low-  
514 density lipoprotein (LDL) cholesterol and triglycerides (TG). a) shows the comparison of GLGC2013  
515 (European) and Biobank Japan, b) GLGC2013 and China Kadoorie Biobank and c) Biobank Japan and  
516 China Kadoorie Biobank.

517 **Figure 2. Associations of polygenic scores** based on established lipid-associated loci with levels of  
518 high-density lipoprotein (HDL), low-density lipoprotein (LDL) cholesterol and triglycerides (TG) in a)  
519 UKHLS, b) HELIC-MANOLIS, c) HELIC-Pomak, d) APCDR-Uganda. Estimates are given as correlation  
520 coefficients. Stars indicate statistically significant associations ( $p < 0.0056$ ).

521 **Figure 3. Regional association plots** for a selection of established lipid-associated loci for UKHLS,  
522 Biobank Japan, APCDR-Uganda, and China Kadoorie Biobank and p-value  $p_{jlim}$  for the trans-ethnic  
523 colocalization with UKHLS.

524 **Tables**

525 **Table 1. Percentage of established lipid-associated loci with evidence of replication** in each target  
 526 study. Results shown separately by strength of association (whether  $p < 10^{-100}$ ) in the discovery study  
 527 (GLGC). Only one SNP was kept for each locus with multiple associated variants in close proximity.  
 528 Regions were defined as 25Kb either side of the lead variant. The credible set contains the reported  
 529 lead variant and variants in LD ( $r^2 > 0.6$ ) with it.

P in GLGC:		$<10^{-100}$			$\geq 10^{-100}$		
Study	Trait	n.s. <sup>a</sup>	Region <sup>b</sup>	Credible <sup>c</sup>	n.s. <sup>a</sup>	Region <sup>b</sup>	Credible <sup>c</sup>
eMERGE	HDL	11.8	11.8	76.5	73.9	19.0	7.2
	LDL	15.4	7.7	76.9	89.3	9.0	1.6
	TG	10.5	10.5	78.9	81.2	15.4	3.4
UKHLS	HDL	5.9	17.6	76.5	81.0	13.7	5.2
	LDL	7.7	15.4	76.9	77.0	16.4	6.6
	TG	0.0	5.3	94.7	82.1	14.5	3.4
CKB	HDL	11.8	5.9	82.4	71.2	16.4	12.4
	LDL	7.7	30.8	61.5	83.6	7.4	9.0
	TG	5.3	15.8	78.9	82.9	10.3	6.8
BBJ	HDL	11.8	11.8	76.5	47.7	19.6	32.7
	LDL	7.7	30.8	61.5	64.8	10.7	24.6
	TG	5.3	10.5	84.2	55.6	12.8	31.6
UG	HDL	11.8	17.6	70.6	73.2	25.5	1.3
	LDL	23.1	7.7	69.2	73.8	24.6	1.6
	TG	42.1	47.4	10.5	79.5	17.1	3.4

530 <sup>a</sup> No variant in the region associated in target set at  $p < 10^{-3}$

531 <sup>b</sup> No variant in the credible set associated in the target set at  $p < 10^{-3}$  but an uncorrelated variant in  
 532 the region is associated in target set at  $p < 10^{-3}$

533 <sup>c</sup> A variant in the credible set is associated in the target set at  $p < 10^{-3}$

534 **Table 2: Associations of polygenic scores** based on established lipid-associated loci and respective  
 535 biomarkers levels in UKHLS, HELIC-MANOLIS, -Pomak, and APCDR-Uganda using a linear mixed  
 536 model analysis.

Trait	N	Correlation (SE <sup>a</sup> )	P-value
<b>UKHLS</b>			
HDL	9706	0.284 (0.010)	8.34x10 <sup>-165</sup>
LDL	9767	0.273 (0.010)	8.38x10 <sup>-155</sup>
Triglycerides	9635	0.203 (0.010)	2.62x10 <sup>-86</sup>
<b>HELIC-MANOLIS</b>			
HDL	1186	0.276 (0.029)	8.65x10 <sup>-20</sup>
LDL	1186	0.230 (0.029)	1.89x10 <sup>-14</sup>
Triglycerides	1176	0.237 (0.030)	3.01x10 <sup>-14</sup>
<b>HELIC-Pomak</b>			
HDL	1078	0.272 (0.030)	9.67x10 <sup>-18</sup>
LDL	1075	0.285 (0.030)	1.35x10 <sup>-18</sup>
Triglycerides	1066	0.235 (0.030)	1.68x10 <sup>-13</sup>
<b>APCDR-Uganda</b>			
HDL	6407	0.121 (0.012)	6.06x10 <sup>-22</sup>
LDL	6407	0.280 (0.012)	1.91x10 <sup>-107</sup>
Triglycerides	6407	0.063 (0.013)	4.46x10 <sup>-7</sup>

537 <sup>a</sup> SE=standard error

538

539 **Table 3: 10,000 simulation runs to assess the performance of trans-ethnic colocalization.**  
540 Phenotypes were simulated for CKB and APCDR-Uganda and trans-ethnic colocalization was run to  
541 compare each to a reference set of 50,000 samples with British ancestry from UK Biobank.

<b>Sample, N</b>	<b>Power</b>	<b>Type I error rate</b>
CKB, 72,473	93.1%	5.2%
APCDR-Uganda, 4,597	73.1%	4.6%
CKB, 4,597	94.8%	4.5%

542



543 **Table 4. Association of established lipid-associated loci with body mass index** by locus replication  
 544 status in APCDR-Uganda. Association results are based on N≥484,680 samples from the meta-  
 545 analysis between GIANT and UK Biobank

Replication	Trait	rs-id	Chr	Position	Annotation	beta	SE	P-value
no	HDL	rs11755393	6	34824636	<i>UHRF1BP1</i>	-0.025	0.002	<b>9.8x10<sup>-48</sup></b>
no	HDL	rs1178979	7	72856430	<i>BAZ1B</i>	-0.010	0.002	<b>3.1x10<sup>-6</sup></b>
no	HDL	rs4731702	7	130433384	<i>KLF14</i>	0.008	0.002	<b>3x10<sup>-7</sup></b>
no	HDL	rs2954033	8	126493746	<i>NSMCE2</i>	-0.010	0.002	<b>6.4x10<sup>-8</sup></b>
no	LDL	rs4245791	2	44074431	<i>ABCG8</i>	0.002	0.002	0.22
no	LDL	rs3846662	5	74651084	<i>HMGCR</i>	0.020	0.002	<b>1.9x10<sup>-35</sup></b>
no	LDL	rs2737229	8	116648565	<i>TRPS1</i>	0.014	0.002	<b>1.9x10<sup>-15</sup></b>
no	LDL	rs635634	9	136155000	<i>IL6R</i>	0.005	0.002	0.03
no	LDL	rs2000999	16	72108093	<i>HPR</i>	0.011	0.002	<b>8.6x10<sup>-8</sup></b>
no	TG	rs1260326	2	27730940	<i>GCKR</i>	-0.011	0.002	<b>1.2x10<sup>-10</sup></b>
no	TG	rs2943641	2	227093745	<i>IRS1</i>	0.006	0.002	<b>5.8x10<sup>-4</sup></b>
no	TG	rs6905288	6	43758873	<i>VEGFA</i>	-0.010	0.002	<b>1.9x10<sup>-9</sup></b>
no	TG	rs11820589	11	116633862	<i>APOA5</i>	-0.003	0.003	0.41
no	TG	rs58542926	19	19379549	<i>TM6SF2</i>	-0.003	0.003	0.33
yes	HDL	rs643531	9	15296034	<i>TTC39B</i>	0.000	0.002	0.92
yes	HDL	rs1800588	15	58723675	<i>LIPC</i>	-0.002	0.002	0.25
yes	HDL	rs3764261	16	56993324	<i>CETP</i>	-0.002	0.002	0.39
yes	HDL	rs16942887	16	67928042	<i>PSKH1</i>	-0.005	0.003	0.06
yes	LDL	rs12740374	1	109817590	<i>CELSR2</i>	0.003	0.002	0.18
yes	LDL	rs1367117	2	21263900	<i>APOB</i>	-0.002	0.002	0.19
yes	LDL	rs6511720	19	11202306	<i>LDLR</i>	0.006	0.003	0.03
suggestive	HDL	rs4841132	8	9183596	<i>PPP1R3B</i>	0.000	0.003	0.88
suggestive	HDL	rs328	8	19819724	<i>LPL</i>	0.005	0.003	0.10
suggestive	HDL	rs769449	19	45410002	<i>APOE</i>	-0.026	0.003	<b>4.4x10<sup>-21</sup></b>
suggestive	HDL	rs386000	19	54792761	<i>LILRB2</i>	0.001	0.002	0.60

546

Figure 1







Figure 2




9q31.1 *ABCA1* - HDL



2p23 *GCKR* - TG



7q11.23 *BAZ1B* - TG



1p13.3 *CELSR2* - LDL

